World’s top intensive care body advises against remdesivir for sickest COVID-19 patients
In light of interim data from the World Health Organization (WHO) global Solidarity trial that showed that remdesivir, an antiviral approved to treat COVID-19 on an emergency basis in the United States and Canada, had little or no effect on overall mortality or duration of hospital stay in hospitalized patients, the European Society of Intensive Care Medicine no longer considers that this drug should be routinely used on COVID-19 patients. Earlier studies had shown some effectiveness at reducing recovery time in severe COVID-19 patients. The new recommendation stemming from the WHO is not binding on health care practitioners but could reduce use of remdesivir as standard of care.
Published: November 13, 2020
CTV NewsRead Article